Charles River Reaffirms 2026 Guidance at Upper End, Sets 2030 Targets
CRL sits 93% above its 52-week low of $144.26.
Summary
Charles River's Investor Day reaffirmed 2026 guidance at the upper end of ranges and introduced long-term targets through 2030, including 5-7% organic revenue CAGR and ~24% non-GAAP operating margin.
Key Events · Earnings and Guidance · CRL
-
2026 Guidance Reaffirmed at Upper End
Management now expects 2026 revenue and non-GAAP EPS at the upper ends of prior ranges (0-1% organic growth; $11.15-$11.45 EPS), reflecting continued favorable biopharmaceutical demand.
-
2030 Long-Term Targets Introduced
Company targets 5-7% organic revenue CAGR from 2027-2030, ~24% non-GAAP operating margin, and low-double-digit non-GAAP EPS CAGR through 2030.
-
Create the Future Savings Program
Expects over $300 million in cumulative savings from 2027 through 2030 via process simplification, automation, and AI-assisted digital tools.
-
Bioanalysis Revenue Target
Bioanalysis revenue expected to grow organically at a high-single-digit CAGR to approximately $450 million by 2030.
Analysis · CRL · Industrial Applications And Services
At its Investor Day, Charles River sharpened its near-term outlook and laid out a concrete long-term roadmap. Management now expects 2026 revenue and non-GAAP EPS at the upper ends of prior ranges — a modest upgrade from the midpoint reaffirmation given in August. The 2030 targets (5-7% organic revenue CAGR, ~24% non-GAAP operating margin, low-double-digit EPS CAGR) give investors a measurable framework for the company's recovery from the 2026 impairments and divestiture losses. The $300 million cumulative savings target from the Create the Future program through 2030 provides a credible margin-expansion lever. This is a meaningful strategic disclosure for a $13.2 billion company emerging from a difficult period.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1615 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRL was trading at $278.01 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.2B. The 52-week trading range was $144.26 to $303.31. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.